Extended Data Table 3 IMbrave150 demographic summary in the BEP versus ITT population

From: Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

  1. Data presented as n (%) unless otherwise indicated. AFP, α-fetoprotein; Atezo, atezolizumab; BEP, biomarker-evaluable population; Bev, bevacizumab; F, female; ITT, intention-to-treat population; M, male; max, maximum; min, minimum.
Back to article page